IRON Insider Trading
Disc Medicine, Inc. | Pharmaceutical Preparations
Comprehensive Trading Performance Summary
The investment history of corporate insiders at Disc Medicine, Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.
Transactions on Chart
Open Full Chart| Filing Date | Trade Date | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-13 04:34 | 2025-03-10 | ORBIMED ADVISORS LLC | Director | SELL | $54.31 | 312,384 | $16,965,606 | 194,209 | -61.7% |
| 2025-02-21 03:36 | 2025-02-18 | Khara Rahul | Officer - Chief Legal Officer | SELL | $54.58 | 1,161 | $63,367 | 37,583 | -3.0% |
| 2025-02-21 03:33 | 2025-02-18 | Savage William Jacob | Officer - Chief Medical Officer | SELL | $54.58 | 1,638 | $89,402 | 68,498 | -2.3% |
| 2025-02-21 03:31 | 2025-02-18 | Yu Jonathan Yen-Wen | Officer - Chief Operating Officer | SELL | $54.58 | 1,610 | $87,874 | 40,555 | -3.8% |
| 2025-02-21 03:38 | 2025-02-18 | Stephenson Pamela | Officer - Chief Commercial Officer | SELL | $54.58 | 3,137 | $171,217 | 69,529 | -4.3% |
| 2025-02-21 03:29 | 2025-02-18 | Franchi Jean M. | Officer - Chief Financial Officer | SELL | $54.58 | 3,136 | $171,163 | 69,530 | -4.3% |
| 2025-02-21 03:27 | 2025-02-18 | Quisel John D | Director, Officer - Chief Executive Officer | SELL | $54.58 | 5,574 | $304,229 | 154,828 | -3.5% |
| 2025-02-05 01:18 | 2025-02-03 | Khara Rahul | Officer - Chief Legal Officer | OPT+S | $55.54 | 7,500 | $416,574 | 14,035 | 0.0% |
| 2025-01-07 01:56 | 2025-01-02 | Khara Rahul | Officer - Chief Legal Officer | OPT+S | $62.75 | 7,500 | $470,658 | 14,035 | 0.0% |
| 2025-01-03 03:13 | 2024-12-30 | Quisel John D | Director, Officer - Chief Executive Officer | OPT+S | $61.95 | 13,012 | $806,057 | 72,065 | 0.0% |
| 2024-12-27 01:18 | 2024-12-23 | Quisel John D | Director, Officer - Chief Executive Officer | OPT+S | $63.14 | 19,820 | $1,251,358 | 72,065 | 0.0% |
| 2024-12-19 03:41 | 2024-12-16 | Quisel John D | Director, Officer - Chief Executive Officer | OPT+S | $66.01 | 12,791 | $844,315 | 72,065 | 0.0% |
| 2024-12-05 03:43 | 2024-12-02 | White William Richard | Director | OPT+S | $64.63 | 1,957 | $126,490 | 0 | 0.0% |
| 2024-11-27 04:03 | 2024-11-25 | Savage William Jacob | Officer - Chief Medical Officer | OPT+S | $65.45 | 14,183 | $928,327 | 40,405 | 0.0% |
| 2024-11-20 02:46 | 2024-11-15 | Savage William Jacob | Officer - Chief Medical Officer | OPT+S | $59.64 | 9,158 | $546,153 | 40,405 | 0.0% |
| 2024-11-06 03:16 | 2024-11-01 | White William Richard | Director | OPT+S | $58.27 | 7,337 | $427,526 | 0 | 0.0% |
| 2024-10-03 23:29 | 2024-10-01 | White William Richard | Director | OPT+S | $51.31 | 201 | $10,312 | 0 | 0.0% |
| 2024-09-18 23:05 | 2024-09-16 | Savage William Jacob | Officer - Chief Medical Officer | SELL | $47.41 | 1,500 | $71,115 | 40,405 | -3.6% |
| 2024-09-05 23:06 | 2024-09-03 | White William Richard | Director | OPT+S | $49.65 | 1,957 | $97,158 | 0 | 0.0% |
| 2024-09-04 23:05 | 2024-09-03 | Savage William Jacob | Officer - Chief Medical Officer | SELL | $50.59 | 1,500 | $75,885 | 41,905 | -3.5% |
| 2024-08-05 23:15 | 2024-08-01 | White William Richard | Director | OPT+S | $43.44 | 201 | $8,731 | 0 | 0.0% |
| 2024-07-03 23:15 | 2024-07-01 | White William Richard | Director | OPT+S | $46.04 | 201 | $9,253 | 0 | 0.0% |
| 2024-06-21 00:27 | 2024-06-17 | Ashiya Mona | Director | BUY | $36.00 | 83,334 | $3,000,024 | 235,391 | +54.8% |
| 2024-06-21 03:00 | 2024-06-17 | Bitterman Kevin | Director | BUY | $36.00 | 222,223 | $8,000,028 | 420,549 | +112.0% |
| 2024-06-21 00:19 | 2024-06-17 | ORBIMED ADVISORS LLC | Director | BUY | $36.00 | 83,334 | $3,000,024 | 235,391 | +54.8% |
| 2024-06-05 23:05 | 2024-06-03 | White William Richard | Director | OPT+S | $36.08 | 1,957 | $70,608 | 0 | 0.0% |
| 2024-05-03 23:05 | 2024-05-01 | White William Richard | Director | OPT+S | $28.63 | 201 | $5,755 | 0 | 0.0% |
| 2024-04-16 01:27 | 2024-04-11 | White William Richard | Director | OPT+S | $31.80 | 2,560 | $81,407 | 0 | 0.0% |
| 2024-03-08 00:40 | 2024-03-05 | Bitterman Kevin | Director | SELL | $73.50 | 26,157 | $1,922,540 | 677,503 | -3.7% |
| 2024-01-26 00:31 | 2024-01-23 | Atlas Venture Fund X, L.P. | 10% owner | SELL | $67.65 | 150,000 | $10,147,500 | 198,326 | -43.1% |
| 2024-01-26 00:33 | 2024-01-23 | Bitterman Kevin | Director | SELL | $67.65 | 102,500 | $6,934,125 | 198,326 | -34.1% |
| 2024-01-13 01:12 | 2024-01-10 | Atlas Venture Fund X, L.P. | 10% owner | SELL | $64.00 | 50,000 | $3,200,000 | 786,160 | -6.0% |
| 2024-01-13 01:12 | 2024-01-10 | Bitterman Kevin | Director | SELL | $64.00 | 20,000 | $1,280,000 | 786,160 | -2.5% |
| 2023-12-21 02:16 | 2023-12-18 | Ashiya Mona | Director | OPT+S | $59.24 | 1,724 | $102,130 | 0 | 0.0% |
| 2023-12-21 02:28 | 2023-12-18 | ORBIMED ADVISORS LLC | Director | OPT+S | $59.24 | 1,724 | $102,130 | 0 | 0.0% |
| 2023-12-16 02:09 | 2023-12-14 | Ashiya Mona | Director | SELL | $56.75 | 433,200 | $24,584,100 | 224,405 | -65.9% |
| 2023-12-16 02:04 | 2023-12-14 | ORBIMED ADVISORS LLC | Director | SELL | $56.75 | 433,200 | $24,584,100 | 224,405 | -65.9% |
| 2023-12-15 00:15 | 2023-12-12 | Bryce Joanne | Officer - Chief Financial Officer | OPT+S | $65.22 | 2,500 | $163,062 | 2,500 | 0.0% |
| 2023-12-15 01:40 | 2023-12-12 | Ashiya Mona | Director | SELL | $58.88 | 134,200 | $7,902,260 | 727,807 | -15.6% |
| 2023-12-15 00:15 | 2023-12-12 | White William Richard | Director | OPT+S | $63.21 | 33,511 | $2,118,240 | 0 | 0.0% |
| 2023-12-15 04:13 | 2023-12-12 | Atlas Venture Fund X, L.P. | 10% owner | SELL | $61.45 | 190,163 | $11,684,585 | 806,160 | -19.1% |
| 2023-12-15 04:14 | 2023-12-12 | Bitterman Kevin | Director | SELL | $61.45 | 76,064 | $4,673,760 | 806,160 | -8.6% |
| 2023-12-15 01:44 | 2023-12-12 | ORBIMED ADVISORS LLC | Director | SELL | $58.88 | 134,200 | $7,902,260 | 727,807 | -15.6% |
| 2023-12-08 00:15 | 2023-12-05 | Bryce Joanne | Officer - Chief Financial Officer | OPT+S | $56.00 | 2,541 | $142,299 | 2,500 | 0.0% |
| 2023-11-28 00:15 | 2023-11-22 | Khara Rahul | Officer - General Counsel | OPT+S | $51.73 | 10,000 | $517,333 | 0 | 0.0% |
| 2023-11-16 01:00 | 2023-11-14 | Khara Rahul | Officer - General Counsel | OPT+S | $50.61 | 4,900 | $248,012 | 0 | 0.0% |
| 2023-11-08 02:22 | 2023-11-03 | Khara Rahul | Officer - General Counsel | OPT+S | $50.00 | 100 | $5,000 | 0 | 0.0% |
| 2023-09-18 23:59 | 2023-09-14 | Atlas Venture Fund X, L.P. | 10% owner | SELL | $53.13 | 357,449 | $18,991,730 | 1,593,785 | -18.3% |
| 2023-09-05 23:16 | 2023-09-01 | Bryce Joanne | Officer - Chief Financial Officer | OPT+S | $52.99 | 1,000 | $52,990 | 1,260 | 0.0% |
| 2023-08-17 23:13 | 2023-08-15 | Bitterman Kevin | Director | SELL | $52.40 | 72,931 | $3,821,584 | 882,224 | -7.6% |
How to Interpret $IRON Trades
Not every insider transaction in Disc Medicine, Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $IRON shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.
Data Source & Accuracy for IRON
Insider activity data for Disc Medicine, Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $IRON, allowing you to follow the capital of those with the most intimate knowledge of the company.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.